Modulating single cell types in the sensory nervous system

NIH RePORTER · NIH · R01 · $542,105 · view on reporter.nih.gov ↗

Abstract

Project Summary/Abstract Some of the best drugs to study and to treat pain and other nervous system disorders originate in the diverse chemistry made by animals and their microbiomes. These chemicals evolved to mediate interactions between animals, often triggering very precise responses in animal neurons. In particular, sensory neurons are major targets because they provoke an almost immediate behavioral reaction from the receiving animal. In humans, the somatosensory nervous system is a major target for drugs to treat pain and other nervous system disorders. Here, we seek to understand how natural compounds from animals and the animal microbiome mediate somatosensory signaling. We will interrogate this problem at the level of individual subclasses of neurons. The sensory system encodes many distinct cell types, each of which is responsible for a very specific type of sensation. For example, there are several different types of neurons that sense different kinds of heat, cold, pain, touch, itch, and bodily position. By applying neuroactive ligands to these natural mixtures of sensory cells, we are able to immediately visualize compounds that target just a single subset of cells, such as those responsible for mechanical or cold pain. In turn, those ligands may provide good drugs or drug leads to mediate the chronic pain conditions that are primarily caused by damage to those neurons. This project will map the functional pharmacology of neurons responsible for sensation, with a focus on pain sensation and central control of pain. At the same time, we will discover new ligands with potential application as tool compounds or as new therapies for chronic pain and other neurological diseases. To do so, our specific aims are to: 1) Discover ligands that target specific cell types in the sensory neurons; 2) Test the therapeutic efficacy of ligands by strategically selecting animal models of disease; and 3) Characterize the physiological targets and off-targets of test compounds in synergy with medicinal chemistry.

Key facts

NIH application ID
10522412
Project number
1R01NS125305-01A1
Recipient
UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH
Principal Investigator
Eric W Schmidt
Activity code
R01
Funding institute
NIH
Fiscal year
2022
Award amount
$542,105
Award type
1
Project period
2022-07-01 → 2027-06-30